BidaskClub downgraded shares of Atrion (NASDAQ:ATRI) from a sell rating to a strong sell rating in a research note issued to investors on Monday, December 18th.
Atrion (NASDAQ:ATRI) traded down $9.10 during trading hours on Monday, reaching $584.35. The company had a trading volume of 2,184 shares, compared to its average volume of 3,474. The stock has a market capitalization of $1,098.98, a price-to-earnings ratio of 32.37 and a beta of 0.85. Atrion has a 52-week low of $454.10 and a 52-week high of $694.00.
Atrion (NASDAQ:ATRI) last released its earnings results on Wednesday, November 8th. The medical instruments supplier reported $4.29 earnings per share (EPS) for the quarter. The firm had revenue of $37.90 million during the quarter. Atrion had a return on equity of 18.34% and a net margin of 22.98%.
The firm also recently declared a quarterly dividend, which was paid on Friday, December 15th. Shareholders of record on Friday, December 1st were issued a dividend of $1.20 per share. This represents a $4.80 dividend on an annualized basis and a yield of 0.82%. The ex-dividend date was Thursday, November 30th. Atrion’s dividend payout ratio (DPR) is 26.59%.
A number of hedge funds and other institutional investors have recently made changes to their positions in ATRI. BNP Paribas Arbitrage SA lifted its holdings in Atrion by 4,800.0% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 196 shares of the medical instruments supplier’s stock worth $126,000 after buying an additional 192 shares during the last quarter. Legal & General Group Plc lifted its holdings in Atrion by 4.3% during the 2nd quarter. Legal & General Group Plc now owns 336 shares of the medical instruments supplier’s stock worth $216,000 after buying an additional 14 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in Atrion by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 438 shares of the medical instruments supplier’s stock worth $282,000 after buying an additional 66 shares during the last quarter. Capital Analysts LLC purchased a new stake in Atrion during the 2nd quarter worth about $434,000. Finally, Voya Investment Management LLC lifted its holdings in Atrion by 10.2% during the 2nd quarter. Voya Investment Management LLC now owns 755 shares of the medical instruments supplier’s stock worth $486,000 after buying an additional 70 shares during the last quarter. 59.01% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/13/atrion-atri-downgraded-to-strong-sell-at-bidaskclub.html.
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.